Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Immodulon batch) formulated as an oral pill (V7)

Immunotherapy

Volumn 5, Issue 10, 2013, Pages 1047-1054

  Butov, Dmytro A ^a   Efremenko, Yuri V ^b   Prihoda, Natalia D ^b   Zaitzeva, Svetlana I ^a   Yurchenko, Larisa V ^b   Sokolenko, Nina I ^b   Butova, Tetyana S ^a   Stepanenko, Anna L ^a   Kutsyna, Galyna A ^c   Jirathitikal, Vichai ^d   Bourinbaiar, Aldar S ^d  

^a KHARKIV NATIONAL MEDICAL UNIVERSITY   (Ukraine)

^b Lisichansk Regional Tuberculosis Dispensary ^*  (Ukraine)

^c Lugansk State Medical University   (Ukraine)

^d Immunitor Inc   (Canada)

Author keywords

cachexia; clinical trial; DOT; imm02; immunomodulator; inflammation; MDR TB; mucosa; NCT01380119; therapeutic vaccine

Indexed keywords

BCG VACCINE; ETHAMBUTOL; HEMOGLOBIN; ISONIAZID; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BACTERIAL CLEARANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEVER; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LUNG TUBERCULOSIS; LYMPHOCYTE COUNT; MALE; MUCOSAL IMMUNITY; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM VACCAE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPUTUM SMEAR; TREATMENT DURATION; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ADULT; BACTERIAL LOAD; BACTERIAL VACCINES; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV; HIV INFECTIONS; HOT TEMPERATURE; HUMANS; MALE; MIDDLE AGED; MYCOBACTERIUM; PHARMACEUTICAL PREPARATIONS; PLACEBOS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; VACCINES, INACTIVATED;

EID: 84885221053     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.110     Document Type: Article

References (32)

1. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: Review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med. 16, 186-193 (2010).
2. Churchyard GJ, Kaplan G, Fallows D, Wallis RS, Onyebujoh P, Rook GA. Advances in immunotherapy for tuberculosis treatment. Clin. Chest Med. 30, 769-782 (2009).
3. Dheda K, Schwander SK, Zhu B, van Zyl-Smit RN, Zhang Y. The immunology of tuberculosis: From bench to bedside. Respirology 15, 433-450 (2010).
4. Doherty TM. Immunotherapy for TB. Immunotherapy 4, 629-647 (2012).
5. Prabowo SA, Groschel MI, Schmidt ED et al. Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines. Med. Microbiol. Immunol. 202, 95-104 (2013). n Recent review on TB immunotherapy and therapeutic vaccines.
6. Stanford J, Stanford C, Grange J. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis. Front. Biosci. 9, 1701-1719 (2004).n Comprehensive review of TB immunotherapy using Mycobacterium vaccae.
7. Bonickse R, Juhasz E. [Description of the new species Mycobacterium vaccae n. sp]. Zentralbl. Bakteriol. Orig. 192, 133-135 (1964).n Original report De scribing discovery of M. vaccae.
8. Lahey T, Arbeit RD, Bakari M et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: A Phase III study in Tanzania. Vaccine 28, 7652-7658 (2010).
9. Dalgleish AG. Therapeutic cancer vaccines: Why so few randomised Phase III studies reflect the initial optimism of Phase II studies. Vaccine 29, 8501-8505 (2011).
10. Hale MW, Rook GA, Lowry CA. Pathways underlying afferent signaling of bronchopulmonary immune activation to the central nervous system. Chem. Immunol. Allergy 98, 118-141 (2012).
11. Yang XY, Chen QF, Li YP, Wu SM. Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: A meta-analysis. PLoS ONE 6, e23826 (2011).
12. Luo Y, Lu S, Guo S. [Immunotherapeutic effect of Mycobacterium vaccae on multi-drug resistant pulmonary tuberculosis]. Zhonghua Jie He He Hu Xi Za Zhi 23, 85-88 (2000).
13. DeBruyn G, Garner P. Mycobacterium vaccae immunotherapy for treating tuberculosis. Cochrane Database Syst. Rev. 1, CD001166 (2003). n Meta-analysis concluding that M. vaccae had no beneficial adjunct effect in TB therapy.
14. Dlugovitzky D, Notario R, Martinel-Lamas D et al. Immunotherapy with oral, heat-killed, Mycobacterium vaccae in patients with moderate to advanced pulmonary tuberculosis. Immunotherapy 2, 159-169 (2010).
15. Devadatta S, Radhakrishna S, Fox W et al. Comparative value of sputum smear examination and culture examination in assessing the progress of tuberculosis patients receiving chemotherapy. Bull. World Health Organ. 34, 573-587 (1966).
16. Migliori GB, Ambrosetti M, Besozzi G, Casali L, Raviglione MC. Prospective multicentre study on the evaluation of antituberculosis treatment results in Italy: Comparison of the culture-versus the smear-based methods. National AIPO. Tuberculosis Study Group. Eur. Respir. J. 13, 900-903 (1999).
17. Bourinbaiar AS, Mezentseva MV, Butov DA et al. Immune approaches in tuberculosis therapy: A brief overview. Expert Rev. Anti Infect. Ther. 10, 381-389 (2012).n Short synopsis of the history of TB immunotherapy.
18. Arjanova OV, Prihoda ND, Yurchenko LV et al. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J. Vaccin. Vaccinat. 1, 103-108 (2010).
19. Butov DA, Pashkov YN, Matveeva SL et al. Phase 2, placebo-controlled trial of an oral immunotherapeutic vaccine in patients with first diagnosed tuberculosis, relapsed TB, and multi-drug resistant (MDR-TB). J. Immune Based Ther. Vaccines 9, 3-12 (2011).
20. Arjanova OV, Butov DA, Prihoda ND et al. One-month immunotherapy trial in treatment-failed TB patients. Open J. Immunol. 1, 50-55 (2011).
21. Arjanova OV, Butov DA, Prihoda ND et al. Therapeutic vaccination of treatment-failed TB patients on ?palliative? support consisting of isoniazid and rifampicin. Mycobact. Dis. doi:10.4172/2161-1068 (2012) (Epub ahead of print).
22. Efremenko YV, Arjanova OV, Prihoda ND et al. Clinical validation of sublingual formulations of Immunoxel (Dzherelo) as an adjuvant immunotherapy in treatment of TB patients. Immunotherapy 4, 273-282 (2012).
23. Butov DA, Efremenko YV, Prihoda ND et al. Adjunct immune therapy of first-diagnosed TB, relapsed TB, treatment-failed TB, multidrug-resistant TB and TB/HIV. Immunotherapy 4, 687-695 (2012).
24. Yew WW, Leung CC. Prognostic significance of early weight gain in underweight patients with tuberculosis. Am. J. Respir. Crit. Care Med. 174, 236-237 (2006).
25. Villamor E, Saathoff E, Mugusi F, Bosch RJ, Urassa W, Fawzi WW. Wasting and body composition of adults with pulmonary tuberculosis in relation to HIV-1 coinfection, socioeconomic status, and severity of tuberculosis. Eur. J. Clin. Nutr. 60, 163-171 (2006).
26. Onyebujoh PC, Abdulmumini T, Robinson S, Rook GA, Stanford JL. Immunotherapy with Mycobacterium vaccae as an addition to chemotherapy for the treatment of pulmonary tuberculosis under difficult conditions in Africa. Respir. Med. 89, 199-207 (1995).
27. Corlan E, Marica C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. 2. Chronic or relapsed disease. Respir. Med. 91, 21-29 (1997).
28. Johnson JL, Kamya RM, Okwera A et al. Randomized controlled trial of Mycobacterium vaccae immunotherapy in non-human immunodeficiency virus-infected Ugandan adults with newly diagnosed pulmonary tuberculosis. The Uganda-Case Western Reserve University Research Collaboration. J. Infect. Dis. 181, 1304-1312 (2000).
29. Efremenko YV, Butov DA, Prihoda ND et al. Randomized, placebo-controlled Phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7). Hum. Vaccin. Immunother. 9(9) doi:10.4161/hv.25280 (2013) (Epub ahead of print).
30. Mwinga A, Nunn A, Ngwira B et al.; LUSKAR collaboration. Mycobacterium vaccae (SRL172) immunotherapy as an adjunct to standard antituberculosis treatment in HIV-infected adults with pulmonary tuberculosis: A randomised placebo-controlled trial. Lancet 360, 1050-1055 (2002).
31. Durban Immunotherapy Trial Group. Immunotherapy with Mycobacterium vaccae in patients with newly diagnosed pulmonary tuberculosis: A randomised controlled trial. Lancet 354, 116-119 (1999).
32. Yang XY, Chen QF, Cui XH, Yu Y, Li YP. Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: A meta-analysis. J. Infect. 60, 320-330 (2010).